Eliquis vs. Pradaxa
See how Eliquis and Pradaxa compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Eliquis and Pradaxa are both oral blood thinners taken twice daily, but they block clotting through different pathways and cause different common side effects.
Eliquis covers DVT prevention after both hip and knee replacement and pediatric VTE treatment from birth, while Pradaxa covers hip replacement only and pediatric VTE from age 8.
Pradaxa is more associated with stomach-related side effects like dyspepsia, while Eliquis's most common reactions are bleeding-related, such as nosebleeds and bruising.
Eliquis vs. Pradaxa Drug Summary
Eliquis
Eliquis (apixaban) is a factor Xa inhibitor, an oral blood thinner used to reduce stroke risk in non-valvular atrial fibrillation and to treat or prevent blood clots like DVT and PE. It is taken as a tablet twice daily, usually 5 mg, with a lower 2.5 mg dose for certain patients based on age, weight, or kidney function.
Pradaxa
Pradaxa (dabigatran) is a direct thrombin inhibitor, a different class of oral blood thinner used to reduce stroke risk in non-valvular atrial fibrillation and to treat or prevent DVT and PE. It is taken as a capsule twice daily, usually 150 mg, with a lower 75 mg dose for people with severe kidney impairment.
Eliquis vs. Pradaxa Side Effects
Eliquis
Pradaxa
Eliquis vs. Pradaxa Dosage
Eliquis
Pradaxa
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg twice daily | Days 1-7 |
| Maximum dose | 2.5 mg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 150 mg twice daily | At the start |
| Maximum dose | 220 mg once daily | Days 2-35 |
| Dose changes | 3 increases | As tolerated |
Eliquis
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg twice daily | Days 1-7 |
| Maximum dose | 2.5 mg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
Pradaxa
| STAGE | DOSE | WHEN |
| Starting dose | 150 mg twice daily | At the start |
| Maximum dose | 220 mg once daily | Days 2-35 |
| Dose changes | 3 increases | As tolerated |
Eliquis vs. Pradaxa Indications
Eliquis
Eliquis is FDA-approved to reduce the risk of stroke in people with non-valvular atrial fibrillation, to treat and prevent recurrent DVT and PE, and to prevent DVT after hip or knee replacement surgery. It is also cleared for VTE treatment in children from birth onward.
Stroke risk reduction in nonvalvular atrial fibrillation
DVT and PE treatment and recurrence prevention
DVT prophylaxis after hip or knee replacement
Pediatric VTE treatment from birth onward
Pradaxa
Pradaxa is FDA-approved to reduce the risk of stroke in people with non-valvular atrial fibrillation, to treat and prevent recurrent DVT and PE, and to prevent DVT after hip replacement surgery. It is approved for pediatric VTE treatment starting at age 8 with the capsule form.
Stroke risk reduction in nonvalvular atrial fibrillation
DVT and PE treatment and recurrence prevention
DVT prophylaxis after hip replacement only
Pediatric VTE treatment from age 8 (capsules)
Eliquis vs. Pradaxa Pros and Cons
Eliquis
Eliquis has one of the broadest FDA approval lists among oral anticoagulants, covering both hip and knee surgery prophylaxis and pediatric use from birth. As a widely prescribed DOAC, it's generally well covered by insurance, though its metabolism creates some drug interaction considerations.
Pros
Approved for DVT prevention after both hip and knee replacement
Approved for pediatric VTE treatment from birth, not just older children
Lower reported rates of GI-related side effects like dyspepsia in trials
Cons
Partly metabolized by CYP3A4, so more potential interactions with strong CYP3A4 inhibitors or inducers
Its reversal agent (andexanet alfa) has a shorter real-world track record than Pradaxa's
Dose selection depends on multiple factors (age, weight, kidney function), adding complexity
Pradaxa
Pradaxa was the first oral direct thrombin inhibitor approved in the US and has long-term outcome data from the large RE-LY trial. Its main trade-offs are a higher rate of stomach-related side effects and more restrictive storage and pediatric age requirements than Eliquis.
Pros
Minimal CYP450 metabolism means fewer interactions with strong CYP3A4 drugs
Dedicated reversal agent (idarucizumab) has been available since 2015, longer than Eliquis's
Longest real-world track record among DOACs, approved in the US since 2010
Cons
Higher reported rates of dyspepsia and other GI side effects than Eliquis
Approved for DVT prevention after hip replacement only, not knee replacement
Capsules are moisture-sensitive and must stay in original packaging
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.